NCT00092443View on ClinicalTrials.gov

Dose Confirmation Efficacy Study (V260-007)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,312

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions
Rotavirus Infections
Interventions
BIOLOGICAL

RotaTeq™, rotavirus vaccine, live, oral, pentavalent

Three doses of RotaTeq™ administered 28 to 70 days apart.

BIOLOGICAL

Comparator: Placebo matching RotaTeq™

Placebo matching RotaTeq™ administered 28 to 70 days apart.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00092443 - Dose Confirmation Efficacy Study (V260-007) | Biotech Hunter | Biotech Hunter